Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bowman Cox

Executive Editor

Washington, DC
Bowman Cox leads the Pink Sheet's coverage of pharmaceutical manufacturing quality issues. He writes and edits articles on the challenges and opportunities that developments in science, technology and regulatory policy pose to drug manufacturers and their quality organizations.

Latest From Bowman Cox

US FDA Invites Warning Letter Follow-Up Inspection Alternative Proposals As Pandemic Persists

With inspectorate grounded by COVID-19, agency cannot clear remediated facilities or approve related applications – unless industry has a better idea.

Quality Compliance

Protecting Drug Manufacturing From COVID: US FDA Offers Directions

Guidance provides agency’s expectations for keeping virus out of drugs and facilities by protecting, monitoring, and excluding workers.

Manufacturing Coronavirus COVID-19

Hope Is Not A Plan: Manufacturing COVID-19 Therapeutics

Duke-Margolis discussion emphasizes biopharma sector must quickly collaborate on manufacturing coronavirus therapeutics likely to be authorized or approved in coming months.

Coronavirus COVID-19 Manufacturing

Drug Quality Focus On Asia, OTCs Supported By US FDA's Second GMP Data Report

OTCs and other "no-application" products remain a drag on overall quality, agency finds in annual quality report, while India and China continue to pose challenges.

OTC Drugs FDA

Protecting Rx Manufacturing From COVID: US FDA Offers Directions For Firms

Guidance provides agency’s expectations for keeping virus out of drugs and facilities by protecting, monitoring, and excluding workers.

Coronavirus COVID-19 Manufacturing

US FDA Warning Letter Questions Takeda’s Support For Quality

Aseptic processing lapses signal deeper problems at Takeda’s Hikari plant.

Enforcement Manufacturing
See All
UsernamePublicRestriction

Register